Drug intelligence / Profile preview

bms-986141

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986141 is an orally active, selective small molecule antagonist of the thrombin receptor protease-activated receptor 4 (PAR4). It was developed as an antithrombotic agent to inhibit platelet aggregation and reduce thrombus formation. BMS-986141 has demonstrated potent inhibition of PAR4-mediated platelet activation and aggregation, with additive antithrombotic effects when combined with other antiplatelet therapies such as aspirin or ticagrelor. The drug has been investigated in phase 1 and phase 2 clinical trials for thrombosis, stroke prevention, and coronary artery disease. Its primary developer is Bristol Myers Squibb[1][5][8].

Other names: BMS986141BMS-986141BMS 986141

Targets

PAR4 (Protease-activated receptor 4)

Beyond the preview

Go deeper on bms-986141.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bms-986141.

Explore the full profile